Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
Novartis’ Canakinumab Fails in Phase III Trials for NSCLC Canakinumab's prospects as an anticancer therapy were already dwindling when a third phase III trial in non-small cell lung cancer (NSCLC) failed to reach its objectives. The most recent setback came from the CANOPY-A study, which included patients with N...
Find More
Juvenile Idiopathic Arthritis (JIA) is an inflammation in the synovial membranes and the most chronic rheumatoid disorder in children and adolescents. The aim of Juvenile idiopathic arthritis treatment is to control pain; to preserve the range of motion (ROM), muscle strength, and function, manage systemic complica...
Find More
Juvenile Idiopathic Arthritis July is Juvenile Idiopathic Arthritis Awareness Month, which is dedicated to making everyone aware of arthritis. The most prevalent form of juvenile arthritis is juvenile idiopathic arthritis (JIA). Diagnosis of juvenile idiopathic arthritis can be difficult as joint pain ca...
Find More
1 in 3 people ageing from 18 to 64 has some type of arthritis as per recent estimates by Arthritis Foundation. There exist more than 100 types of Arthritis, and Juvenile Idiopathic Arthritis (JIA) is the most common form of rheumatic arthritis prevalent in children. JIA is a collective term for all the form forms o...
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
